Treatment history and baseline viral load, but not viral tropism or CCR-5 genotype, influence prolonged antiviral efficacy of highly active antiretroviral treatment

AIDS

Volumn 12, Issue 16, 1998, Pages 2193-2202

  Bratt, Göran ^a   Karlsson, Anders ^a   Leandersson, Ann Charlotte ^b   Albert, Jan ^b   Wahren, Britta ^a   Sandström, Eric ^a  

^a STOCKHOLM SÖDER HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Antiretroviral therapy; CCR 5 genotype; CD4 count; HIV RNA; MT 2 tropism; Protease inhibitors; Treatment response; Viral load

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; GLYCOPROTEIN GP 160; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INDINAVIR; LAMIVUDINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RITONAVIR; VIRUS RECEPTOR; VIRUS RNA; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; ARTICLE; FEMALE; GENOTYPE; HETEROZYGOSITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PRIORITY JOURNAL; REGRESSION ANALYSIS; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; LONGITUDINAL STUDIES; MALE; PROTEASE INHIBITORS; REGRESSION ANALYSIS; RNA, VIRAL; STATISTICS, NONPARAMETRIC; TROPISM; VIRAL LOAD;

EID: 0032511927     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199816000-00015     Document Type: Article

References (55)

1. Pantaleo G, Graziosi C, Fauci A: The immunopathogenesis of human immunodeficiency virus infection. N Engl J Med 1993, 328:327-335.
2. Michael NL, Valley M, Burke DS, Redfield RR: Viral DNA and mRNA expression correlate with the stage of human immunodeficiency virus (HIV) type 1 infection in humans: evidence for viral replication in all stages of HIV disease. J Virol 1992, 66:310-316.
3. Schnittman SM, Psallidopoulos MC, Lane HC, et al.: The reservoir for HIV-1 in human peripheral blood is a T cell that maintains expression of CD4. Science 1989, 245:305-308.
4. Hessol NA, Byers RH, Lifson AR, et al.: Relationship between AIDS latency period and AIDS survival time in homosexual and bisexual men. J Acquir Immune Defic Syndr 1990, 3:1078-1085.
5. Hammer SM: Advances in antiretroviral therapy and viral load monitoring. AIDS 1996, 10 (suppl 3):S1-S11.
6. Harrigan R: Measuring viral load in the clinical setting. J Acquir Immune Defic Syndr Hum Retrovirol 1995, 10 (suppl 1):S34-S40.
7. Jurriaans S, Van Gemen B, Weverling GJ, et al.: The natural history of HIV-1 infection: virus load and virus phenotype independent determinants of clinical course? Virology 1994, 204:223-233.
8. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA: Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996, 272:1167-1170.
9. Mellors JW, Kingsley LA, Rinaldo CR Jr, et al.: Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995, 122:573-579.
10. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995, 373:123-126.
11. Wei X, Ghosh SK, Taylor ME, et al.: Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995, 373:117-122.
12. Carpenter CC, Fischl MA, Hammer SM, et al.: Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. JAMA 1997, 277:1962-1969.
13. Koot M, Keel IP, Vos AH, et al.: Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med 1993, 118:681-688.
14. Koot M, Vos AH, Keet RP, et al.: HIV-1 biological phenotype in long-term infected individuals evaluated with an MT-2 cocultivation assay. AIDS 1992, 6:49-54.
15. Tersmette M, Lange JM, de Goede RE, et al.: Association between biological properties of human immunodeficiency virus variants and risk for AIDS and AIDS mortality. Lancet 1989, i:983-985.
16. Karlsson A, Parsmyr K, Sandström E, Fenyö EM, Albert J: MT-2 cell tropism as prognostic marker for disease progression in human immunodeficiency virus type 1 infection. J Clin Microbiol 1994, 32:364-370.
17. Schellekens PT, Tersmette M, Roos MT, et al.: Biphasic rate of CD4+ cell count decline during progression to AIDS correlates with HIV-1 phenotype. AIDS 1992, 6:665-669.
18. Choe H, Farzan M, Sun Y, et al.: The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996, 85:1135-1148.
19. Dragic T, Litwin V, Allaway GP, et al.: HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996, 381:667-673.
20. Deng H, Liu R, Ellmeier W, et al.: Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996, 381:661-666.
21. Alkhatib G, Combadiere C, Broder CC, et al.: CC CKR5: a RANTES, MIP-1 alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996, 272:1955-1958.
22. Feng Y, Broder CC, Kennedy PE, Berger EA: HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996, 272:872-877.
23. Samson M, Libert F, Doranz BJ, et al.: Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996, 382:722-725.
24. Dean M, Carrington M, Winkler C, et al.: Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 1996, 273:1856-1862.
25. Michael NL, Chang G, Louie LG, et al: The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression. Nat Med 1997, 3:338-340.
26. Eugen-Olsen J, Iversen AK, Garred P, et al.: Heterozygosity for a deletion in the CKR-5 gene leads to prolonged AIDS-free survival and slower CD4 T-cell decline in a cohort of HIV-seropositive individuals. AIDS 1997, 11:305-310.
27. Gulick K, Mellors J, Havlir D, et al.: Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997, 337:734-739.
28. Hammer S, Squires K, Hughes M, et al.: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997, 337:725-733.
29. Karlsson A, Parsmyr K, Aperia K, Sandström E, Fenyö EM, Albert J: MT-2 cell tropism of human immunodeficiency virus type 1 isolates as a marker for response to treatment and development of drug resistance. J Infect Dis 1994, 170:1367-1375.
30. Kuritzkes DR, Quinn JB, Benoit SI, et al.: Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients. AIDS 1996, 10:975-981.
31. Boucher CA, Lange JM, Miedema FF, et al.: HIV-1 biological phenotype and the development of zidovudine resistance in relation to disease progression in asymptomatic individuals during treatment. AIDS 1992, 6:1259-1264.
32. Carpenter CC, Fischl MA, Hammer SM, et al.: Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. JAMA 1996, 276:146-154.
33. Centers for Disease Control. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. JAMA 1993, 269:729-730.
34. World Health Organization: WHO case definitions for AIDS surveillance in adults and adolescents. Wkly Epidemiol Rec 1994, 69:273-275.
35. Scarlatti G, Hodara V, Rossi P, et al.: Transmission of human immunodeficiency virus type 1 (HIV-1) from mother to child correlates with viral phenotype. Virology 1993, 197:624-629.
36. Delta Coordinating Committee: Delta: a randomized double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996, 348:283-291.
37. Tätkenheuer G, Theisen A, Rockstroh J, et al.: Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. AIDS 1997, 11:F113-F116.
38. Hughes MD, Johnson VA, Hirsch MS, et al.: Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team. Ann Intern Med 1997, 126:929-938.
39. Katzenstein DA, Hammer SM, Hughes MD, et al.: The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. N Engl J Med 1996, 335:1091-1098.
40. Brun-Vézinet F, Boucher C, Loveday C, et al.: HIV-1 viral phenotype, and resistance in a subset of drug-naive participants from the Delta trial. Lancet 1997, 350:983-990.
41. Mellors JW, Munoz A, Giorgi JV, et al.: Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997, 126:946-954.
42. D'Aquila RT, Johnson VA, Welles SL, et al.: Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. Ann Intern Med 1995, 122:401-408.
43. Delforge ML, Liesnard C, Debaisieux L, Tchetcheroff M, Farber CM, Van Vooren IP: In vivo inhibition of syncytium-inducing variants of HIV in patients treated with didanosine [letter]. AIDS 1995, 9:89-90,
44. St Clair M, Hartigan P, Andrews J, Vavro C, Simberkoff M, Hamilton J: Zidovudine resistance, syncytium-inducing phenotype, and HIV disease progression in a case-control study. J Acquir Immune Defic Syndr 1993, 6:891-897.
45. Schooley RT, Ramirez-Ronda C, Lange JM, et al.: Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcilabine or didanosine compared with zidovudine monotherapy. J Infect Dis 1996, 17:1354-1366.
46. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD: HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996, 271:1582-1586.
47. Perelson AS, Esunger P, Cao Y, et al.: Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997, 387:188-191.
48. Wong J, Hezareh M, Gunthard H, et al.: Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997, 278:1291-1295.
49. Finzi D, Hermankova M, Pierson T, et al.: Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997, 278: 1295-1300.
50. Graham NM, Piantadosi S, Park LP, Phair JP, Rinaldo CR, Fahey JL: CD4+ lymphocyte response to zidovudine as a predictor of AIDS-free time and survival time. J Acquir Immune Defic Syndr 1993, 6:1258-1266.
51. Eastebrook PJ, Emami J, Gazzard B: Rate of CD4 cell decline and prediction of survival in zidovudine-treated patients. AIDS 1993, 7:795-967.
52. Kahn JO, Lagalos SW, Richman DD, et al.: A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. N Engl J Med 1992, 327:581-587.
53. Lambert JS, Seidlin M, Reichman RC, et al.: 2′,3′-dideoxyinosine (ddl) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase 1 trial. N Engl J Med 1990, 322:1333-1340.
54. Cooper D, Katlama C, Montaner J, Collis P: Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet 1997, 349:1413-1421.
55. Stein DS, Drusano GL: Modeling of the change in CD4 lymphocyte counts in patients before and after administration of the human immunodeficiency virus protease inhibitor indinavir. Antimicrob Agents Chemother 1997, 41:449-453.